Crispr Therapeutics price target raised to $50 from $42 at RBC Capital

RBC Capital raised the firm’s price target on Crispr Therapeutics (CRSP) to $50 from $42 and keeps a Sector Perform rating on the shares after its better than expected Q3 earnings. The firm “appreciate all the progress” but still remains on the sidelines with a cautious stance on Casgevy’s launch and pending further progress on the rest of the pipeline, the analyst tells investors in a research note.